Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Advent BioServices announces Head of PD and R&D, Alessandra De Riva
https://www.adventbio.uk/post/welcome-to-alessandra-de-riva
Reg....
So very happy for you and your loved ones. Wonderful news!
Very appreciative of your efforts in posting your summary of our messy world. May the Force be with you!
And,
BP Advertising revenue stream to media………$6Billion + annually
vs.
NWBO Advertising revenue stream to media….$0
No, no added comments that would be of interest to the Board.
DC
Wishing you strength and peace. Prayers on the way.
Standing ovation.
I’m sure you know this Red57, but perhaps our newer members do not:
Link is for UCLA and other Agile sites
University of California, Los Angeles (Los Angeles, CA)
Principal Investigator: Phioanh Nghiemphu, MD
Contact for Patients: Emy Filka
(310) 794-3521
efilka@mednet.ucla.edu
https://www.gcaresearch.org/gbm-agile/trial-sites/
“Sold a company and don't need to the money. Research biotechs regularly. Am critical of poorly run companies that take advantage of shareholders, which is why I'm here.”
How very noble, HyGro. Here I am assuming you are engaged in “brain picking” noting the many experts on this MB and the wealth of information and personal DD available here. Silly me!
Sir Pump…
What exactly are you growing in your fields? Do you need some help with the harvest?
Correction - Post 452194
REF: Further comments on media coverage…..News articles are not revenue, paid advertising is $$$.
REF: Further comments on media coverage…..New articles are not revenue, paid advertising is $$$.
The link below (U.S. Dept of Commerce) presents an easy-read, overview of the biopharmaceutical industry in the US.
The direct and indirect economic impact of this industry is significant;
the job numbers are significant.
It is noteworthy to point out that within these stats is approximately a $6 billion+ revenue stream that the pharmaceutical industry feeds to the media in advertising buys. This last point might indicate why the media may be hesitant to give attention to NWBO’s coming disruption and risk ruffling feathers of their most valued, deep-pocket clients. By the way, the DTC (Direct to Consumer) US media ads in which the pharma industry engages is not allowed in the rest of the world except for New Zealand.
https://www.selectusa.gov/pharmaceutical-and-biotech-industries-united-states
https://www.fiercepharma.com/special-report/top-10-ad-spenders-big-pharma-for-2020
Apologies if this new Advent career opportunity has already been posted:
https://adventbio.peoplehr.net/Pages/JobBoard/Opening.aspx?v=2e412027-d46e-4056-9583-9bc4667812dc
Last line of 10K document:
“On February 28, 2022, the Company further extended the suspension of the exercise rights of approximately 295.7 million warrants and options held by certain of the Company’s officers and board of directors until at least March 31, 2022. Additionally, certain investors also agreed to suspend exercise rights of approximately 18.6 million warrants until May 15, 2022.”
Lykiri…..
Thank you for sharing this interview with Kwok Pang, Chief Operating Officer of Autolomous. It is interesting to note how critical data management is in the biotech industry:
NIH Order: The Institutions It Funds Must Share their Data Publicly
In 2023, the biggest global funder of research will require a data-management plan in grant applications
https://www.criver.com/eureka/nih-order-institutions-it-funds-must-share-their-data-publicly
Side note: Charles River Lab
UK Cell and Gene Therapy Expansion
https://www.criver.com/insights/uk-cell-and-gene-therapy-expansion
So very sorry for your loss
“So true but if the evidence in the journal article is as good as we think and news gets out about current and near term expected manufacturing capability,…..”
See bottom of page - CRL career openings
https://jobs.criver.com/go/Cell-and-Gene-Therapy-Main-Page/8831700/
Thank you Reefrad.
Lykiri’s post presents an overview of Advent Bio/Automolous
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166801109
Latest News from Autolomous: (9 hrs ago)
https://autolomous.com/news/
Of interest:
UCLA research shows why immune checkpoint blockade impedes but does not stop glioblastoma progression - Robert Prins
https://cancer.ucla.edu/Home/Components/News/News/1776/1631
Truly appreciate this recent and most excellent post.
I’m a bit behind my reading this weekend, but has this been posted:
“Speculation is sky high that NWBO is on the verge of major success …”
https://microcapdaily.com/northwest-biotherapeutics-inc-otcmkts-n-as-sawston-uk-manufacturing-facility-completed-phase-iii-top-line-data-looming/
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
https://www.merck.com/news/merck-announces-withdrawal-and-refiling-under-the-hart-scott-rodino-act-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/
I obviously missed it.
Has this been posted:
Re: Marnix Bosch presentation January 2022…Boston
https://glioblastoma-drugdevelopment.com/speaker/marnix-bosch-2/